{
    "other_tests": [
        {
            "procedure_name": "Genetic Analysis",
            "date": "Not specified",
            "findings": "Heterozygous mutation in exon 3 of the FGF23 gene (c.536G /H11022A, p.Arg179Gln) confirming ADHR.",
            "changes_over_time": "Not specified"
        },
        {
            "procedure_name": "Withdrawal of Rickets Medication",
            "date": "At age 5.6 years",
            "findings": "FGF23 values nearly doubled within a week after withdrawal, with declining serum phosphate levels.",
            "changes_over_time": "Phosphate loss remained evident after 4 weeks with TRP values similar to those before withdrawal."
        },
        {
            "procedure_name": "Bone Metabolic Response Monitoring",
            "date": "Beginning at age 5.6 years when medication was withdrawn",
            "findings": "FGF23 remained within reference range but elevated for the level of hypophosphatemia.",
            "changes_over_time": "After medication withdrawal, serum phosphate levels continued to decline and were not normalized until iron supplementation began."
        },
        {
            "procedure_name": "Iron Supplementation",
            "date": "Started at age 8.1 years",
            "findings": "Serum iron and ferritin levels improved, TRP and TmP/GFR eventually normalized.",
            "changes_over_time": "Rickets medication could be halved twice and fully withdrawn by age 9.3 years; phosphate and iron metabolism remained normal following withdrawal."
        }
    ]
}